Apolipoprotein A5 gene −1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan

Abstract Background: The –1131T>C polymorphism in the apolipoprotein gene A5 (APOA5) was found to be associated with increased levels of plasma triglyceride and decreased levels of high-density lipoprotein cholesterol (HDL-C), which are characteristic dyslipidemic components of metabolic syndrome. This study aimed to identify a link between this polymorphism and the risk of metabolic syndrome. Methods: The sample population comprised 615 unrelated subjects, 18.7% of whom had metabolic syndrome. Genotypes were determined via polymerase chain reaction, restriction mapping with MseI, and gel electrophoresis. Results: A significantly higher level of triglycerides and a lower level of HDL-C were noted in carriers of the –1131C allele than in the non-carriers (p<0.001 and p=0.044, respectively). The frequency of the –1131C allele in the metabolic syndrome-affected subjects was significantly higher than that of the group of unaffected subjects (37.4% vs. 27.7%, p=0.004). Even after adjusting for age, gender, smoking, regular exercise, and waist-to-hip ratio, the APOA5 –1131C allele carriers remained significantly associated with an increased risk of metabolic syndrome (OR=1.77, 95% CI, 1.13–2.77; p=0.012). Conclusions: These results indicate that the association of APOA5 –1131T>C polymorphism with dyslipidemia can also contribute to an increased susceptibility to metabolic syndrome in the Chinese, as a result of its effect on triglyceride metabolism. Clin Chem Lab Med 2008;46:1714–9.

[1]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[2]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[3]  P. Björntorp.  Metabolic Implications of Body Fat Distribution , 1991, Diabetes Care.

[4]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[5]  G. Mcclearn,et al.  Genetic and environmental influences on serum lipid levels in twins. , 1993, The New England journal of medicine.

[6]  C. Bouchard,et al.  Genetics and the metabolic syndrome. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[7]  J. Ribalta,et al.  ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. , 1999, Circulation.

[8]  H. Ginsberg,et al.  The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis , 2000, Journal of cardiovascular risk.

[9]  J. Ordovás,et al.  Genetic determinants of plasma lipid response to dietary intervention: the role of the APOA1/C3/A4 gene cluster and the APOE gene , 2000, British Journal of Nutrition.

[10]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[11]  K. V. van Dijk,et al.  Protection From Obesity in Mice Lacking the VLDL Receptor , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[13]  P. Reitsma,et al.  Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.

[14]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[15]  S. Tomura,et al.  Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren , 2002, Human Genetics.

[16]  R. Chamuleau,et al.  Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. , 2002, Biochemical and biophysical research communications.

[17]  Shotai Kobayashi,et al.  The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. , 2002, Atherosclerosis.

[18]  B. Tomlinson,et al.  APOA5‐1131T>C polymorphism is associated with triglyceride levels in Chinese men , 2003, Clinical genetics.

[19]  Medha Kulkarni,et al.  Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. , 2003, Journal of lipid research.

[20]  J. W. Gallagher,et al.  Structure and Interfacial Properties of Human Apolipoprotein A-V* , 2003, Journal of Biological Chemistry.

[21]  K. Chien,et al.  A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. , 2003, Human molecular genetics.

[22]  X. Adiconis,et al.  The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore Published, JLR Papers in Press, September 1, 2003. DOI 10.1194/jlr.M300251-JLR200 , 2003, Journal of Lipid Research.

[23]  M. Reilly,et al.  The Metabolic Syndrome: More Than the Sum of Its Parts? , 2003, Circulation.

[24]  K. V. van Dijk,et al.  ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* , 2004, Journal of Biological Chemistry.

[25]  Len A Pennacchio,et al.  Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. , 2004, Biochemical and biophysical research communications.

[26]  E. Tai,et al.  Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? , 2004, Diabetes care.

[27]  Z. Prohászka,et al.  Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. , 2004, Atherosclerosis.

[28]  Huadan Xue,et al.  Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population , 2004, Clinical genetics.

[29]  L. Hsu,et al.  Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. , 2006, Atherosclerosis.

[30]  Y. Uehara,et al.  Strong linkage disequilibrium and association of -1131T>C and c.553G>T polymorphisms of the apolipoprotein A5 gene with hypertriglyceridemia in a Japanese population. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[31]  F. Kronenberg,et al.  APOA5 variants and metabolic syndrome in Caucasianss⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of three tables, one figure. Published, JLR Papers in Press, September 3, 2007. , 2007, Journal of Lipid Research.

[32]  H. Yoshida,et al.  Prediction of genetic risk for metabolic syndrome. , 2007, Atherosclerosis.

[33]  J. Fruchart,et al.  Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome , 2007, Clinical chemistry and laboratory medicine.

[34]  A. Kondacs,et al.  Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke , 2007, Journal of Molecular Neuroscience.

[35]  B. Melegh,et al.  Apolipoprotein A5 IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[36]  B. Melegh,et al.  Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[37]  B. Melegh,et al.  Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome , 2008, Pathology & Oncology Research.

[38]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .